Abstract:Introduction Tacrolimus is a mainstay of immunosuppression after solid organ transplant to prevent organ rejection. While it has several well-established toxicities including kidney injury and central nervous system disturbances, its association with diffuse lung injury is rare. Case Description A 52-year-old man who underwent heart transplantation for genetic cardiomyopathy presented to the clinic three weeks post-transplant with subjective fever, night sweats, and exertional dyspnea. He was maintained on standard immunosuppression with tacrolimus, mycophenolate mofetil, and prednisone taper. Extensive workup for bacterial, viral, and fungal infections was unremarkable. Serial surveillance protocol right heart catheterizations showed normal filling pressures and hemodynamics, with no evidence of rejection on endomyocardial biopsies. CT chest, abdomen, and pelvis (Image A) at eight weeks since the first reported symptom onset was only notable for a new 5 mm lung nodule. The patient had gradually progressive dyspnea and hypoxia for which he underwent serial imaging. At twelve weeks, CT chest showed progression to multiple bilateral pleural-based lung nodules measuring up to 8mm. FDG-PET/CT (Image B) showed low-level activity and FDG uptake in some nodules concerning for malignancy or atypical infection. Given the peripheral location of the nodules, video-assisted thoracoscopic surgery and wedge resection was performed. Histopathology revealed nodules with abscess formation and fibrin deposits with no evidence of malignancy, granuloma, or infection. At six months, CT chest (Image C) revealed new diffuse bilateral ground glass opacities. Bronchoalveolar lavage showed no evidence of atypical microbial growth. After extensive discussions with pulmonology and infectious disease consultants, drug toxicity secondary to Tacrolimus was presumed to be the culprit. He was switched to Cyclosporine. After four weeks of Tacrolimus discontinuation, he had resolution of symptoms, and repeat imaging (Image D) demonstrated complete resolution of lung opacities with decreasing size of nodules. Tacrolimus was discontinued indefinitely. Conclusion Though described in case series in patients with rheumatoid arthritis, to the best of our knowledge, this is the first reported case of Tacrolimus-associated diffuse lung injury after a cardiac transplant. Extrapolating from data for rheumatoid arthritis, the lung injury is hypothesized to be a result of inflammatory cytokine-mediated endothelial injury. This could potentially explain the FDG uptake seen in our patient. Tacrolimus-associated diffuse lung injury, although rare, should be considered in patients who present with diffuse infiltrates, after appropriate workup to exclude other processes including malignancy and infection.

Severe Acute Cellular Rejection With High-Grade Lymphocytic Bronchiolitis Following Transition from Tacrolimus to Belatacept in a Lung Transplantation Recipient: A Case Report

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Belatacept for Maintenance Immunosuppression in Lung Transplantation

Belatacept for renal rescue in lung transplant patients

Conversion to belatacept after lung transplantation: Report of 10 cases

A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation

Belatacept Versus Tacrolimus for Kidney Transplant Recipients of Deceased Donors With Acute Kidney Injury: US National Database Study

A Pilot Randomized Controlled Trial of De Novo Belatacept-based Immunosuppression After Lung Transplantation

Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

Acute rejection post lung transplant

Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept

Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol

Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients

Belatacept based immunosuppression: What and when to combine?

Tacrolimus-Induced Diffuse Lung Injury

Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials

Use of Sirolimus in Lung Transplantation: A Single Center Experience

Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

Costimulation Blockade with Belatacept in Renal Transplantation.

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

An Unexpectedly High Incidence of Invasive Fungal Diseases in Solid Organ Transplant Recipients on Belatacept for Organ Rejection Prophylaxis: A Single Center Retrospective Cohort Study